James Gillespie
Interventional Pain Medicine · Birmingham, ALNPI 1376078808
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.0%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Boston Scientific at 45.2% of the total. Reporting peaked in 2023 at $3,092 and has fallen 56.0% since, to $1,361 in 2025.
Across 228 payments — averaging $35.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Medtronic$3K
- Forte Bio-pharma LLC$361
- Collegium Pharmaceutical, Inc.$246
- SPR Therapeutics, Inc$167
- Scilex Pharmaceuticals Inc.$153
- plus $963 from 18 others
What the payments were for
- Grants$2,50031%
- Travel & lodging$1,60420%
- Food & beverage$3,98749%
- Education$421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 95 | $3,680 |
| Medtronic | 3 | $2,564 |
| Forte Bio-pharma LLC | 42 | $361 |
| Collegium Pharmaceutical, Inc. | 13 | $246 |
| SPR Therapeutics, Inc | 14 | $167 |
| Scilex Pharmaceuticals Inc. | 8 | $153 |
| Saluda Medical Americas, Inc. | 7 | $136 |
| AstraZeneca | 6 | $126 |
| Abbott | 7 | $120 |
| Spinal Simplicity, LLC | 4 | $111 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $106 |
| Almatica Pharma LLC | 2 | $46 |
| Indivior Inc. | 2 | $43 |
| Hikma Pharmaceuticals USA | 2 | $42 |
| Pacira Pharmaceuticals Incorporated | 1 | $36 |
| IBSA Pharma Inc. | 2 | $31 |
| Azurity Pharmaceuticals, Inc. | 2 | $30 |
| Braeburn Inc. | 1 | $27 |
| Vertos Medical, Inc. | 5 | $25 |
| Si-bone, Inc. | 1 | $23 |
| MML US, Inc. | 2 | $18 |
| Trevena, Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMED$2,500
- WaveWriter Alpha Prime 16$770
How this compares
$8,134 in reported general payments places this provider in the 65th percentile of 33 interventional pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 3,928 | $136,945 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 4,380 | $116,077 |
| ProlateOxycodone Hcl/Acetaminophen | 35 | $96,153 |
| Gabapentin | 2,656 | $38,990 |
| BelbucaBuprenorphine Hcl | 38 | $38,561 |
| Xtampza ErOxycodone Myristate | 58 | $35,203 |
| Buprenorphine | 115 | $28,102 |
| OxycontinOxycodone Hcl | 55 | $23,453 |
| Pregabalin | 1,181 | $21,531 |
| Diclofenac Sodium | 294 | $10,942 |
| Tizanidine Hcl | 1,057 | $10,546 |
| Lidocaine | 113 | $10,388 |
| SavellaMilnacipran Hcl | 12 | $8,827 |
| Baclofen | 593 | $7,788 |
| Morphine Sulfate ErMorphine Sulfate | 181 | $5,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Forte Bio-pharma LLCProlate | $361 | $96,15335 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $246 | $73,76396 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine Hcl | $42 | $35,637362 claims |
| AbbVieSavella | $14 | $8,82712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 interventional pain medicine providers in Alabama.
Other interventional pain medicine in Birmingham
- Michael KendrickBirmingham$90K
- Ryan AlmeidaBirmingham$14K
- Richard ThomaBirmingham$6K
- Anna MelerineBirmingham$5K
- Audra EasonBirmingham$5K
- Kenneth VarleyBirmingham$4K
- Victor MendozaBirmingham$165
- Bradley WargoMuscle Shoals$41K
- Jacob VellaMontgomery$28K
- John IronsVestavia$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.